Gene Therapy for Kids’ Deadly Muscle Disease Fails to Reach Trial Goal

  • 📰 BNNBloomberg
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 50%

Business Business Headlines News

Business Business Latest News,Business Business Headlines

Sarepta Therapeutics Inc. said a trial of its gene therapy for Duchenne muscular dystrophy did not meet its main goal in a trial, a setback for the company as it seeks to widen approval for the treatment to an older group.

Pipe and Fittings Distributor MRC Global Explores Potential SaleXerox Selling $500 Million Loan to Repurchase Icahn’s SharesTraders Bet 10-Year Yields to Revisit 5% With Refunding in FocusBlue-Chip Borrowers Rush to Issue Debt Ahead of Fed MeetingUS Treasury Cuts Quarterly Borrowing Estimate to $776 BillionNetanyahu’s ‘Mr. Security’ Persona Fades as Rivals Want Him OutOct. 31 is the deadline for the underused housing tax.

Lawrence Seaway strikes overUnifor reaches tentative contract agreement with Stellantis, ending brief strikeMajor drink brands launch more non-alcoholic drinks as 'sober curious' trend growsCanada plans college crackdown amid foreign student troubles​The Daily Chase: More bank layoffs; Corus earningsGeneral Motors and Stellantis in talks with United Auto Workers to reach deals that mirror Ford'sHigher-for-longer rates could reduce worker bargaining power: economist​The Daily Chase:...

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 83. in BUSİNESS

Business Business Latest News, Business Business Headlines